Loading
A phase 3 trial testing QLC5508 in oesophageal cancer, now recruiting.
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Oesophageal Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT07463573, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open-Label, Multicenter Phase III Study of QLC5508 Versus Investigator's Choice Chemotherapy in Pretreated Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCC). Planned enrolment is 466 participants (estimated). The study started in 2026-04-20 and primary completion is expected in 2028-06-05. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QLC5508, Qilu Pharmaceutical.
Shares QLC5508, Qilu Pharmaceutical.
Shares QLC5508, Qilu Pharmaceutical.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares QLC5508, Qilu Pharmaceutical.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/